HC Wainwright & Co. Reiterates Buy on Pelthos Therapeutics, Maintains $60 Price Target

HC Wainwright & Co. analyst Brandon Folkes has reiterated a Buy rating on Pelthos Therapeutics (AMEX: PTHS) and maintained a price target of $60 for the stock. This endorsement suggests continued confidence in the company's performance and potential growth.